BIOGEN INC. - COMMON STOCK

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

19 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

29 Sep 2023 16:06:00 By Nasdaq GlobeNewswire

Biogen Completes Acquisition of Reata Pharmaceuticals

26 Sep 2023 08:59:54 By Nasdaq GlobeNewswire

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

25 Sep 2023 01:02:57 By Nasdaq GlobeNewswire

Biogen Appoints Jane Grogan as Head of Research

06 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

04 Aug 2023 22:41:32 By Nasdaq GlobeNewswire

Biogen to Acquire Reata Pharmaceuticals

28 Jul 2023 07:05:44 By Nasdaq GlobeNewswire

Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023

19 Jul 2023 19:30:00 By Nasdaq GlobeNewswire

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

06 Jul 2023 20:00:00 By Nasdaq GlobeNewswire

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

30 Jun 2023 16:06:00 By Nasdaq GlobeNewswire

Biogen Announces Changes to Its Board of Directors

12 Jun 2023 17:14:01 By Nasdaq GlobeNewswire

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

09 Jun 2023 18:45:00 By Nasdaq GlobeNewswire

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease

15 May 2023 19:30:00 By Nasdaq GlobeNewswire

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

25 Apr 2023 15:04:23 By Nasdaq GlobeNewswire

Biogen Appoints Adam Keeney as Head of Corporate Development

04 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting

30 Mar 2023 19:30:00 By Nasdaq GlobeNewswire

Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

30 Mar 2023 19:30:00 By Nasdaq GlobeNewswire

New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease

29 Mar 2023 08:45:00 By Nasdaq GlobeNewswire

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

22 Mar 2023 20:32:40 By Nasdaq GlobeNewswire

Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

16 Mar 2023 06:30:14 By Nasdaq GlobeNewswire